CEOCast.com Interviews Aethlon Medical CEO.SAN DIEGO -- Aethlon Medical, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :AEMD AEMD Automotive Electric Motor Drive (US Department of Energy program) ) announced today that its Chairman & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , James A. Joyce was interviewed today by CEOCast.com. The interview can be accessed at www.ceocast.com through Friday, April 8th. Mr. Joyce discussed Aethlon's upcoming clinical trials for treating HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. and Hepatitis-C patients, and also detailed the Company's strategy to commercialize its Hemopurifier(TM) treatment technology as a first line of defense against drug and vaccine resistant bioweapons. About Aethlon Medical Aethlon Medical is pioneering the development of viral filtration devices to treat HIV/AIDS HIV/AIDS Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome , Hepatitis-C (HCV HCV abbr. hepatitis C virus HCV 1 Hepatitis C virus, see there 2. Human coronavirus. See Coronavirus. ), and pathogens that are mass casualty biological warfare biological warfare, employment in war of microorganisms to injure or destroy people, animals, or crops; also called germ or bacteriological warfare. Limited attempts have been made in the past to spread disease among the enemy; e.g. candidates. Each treatment application employs the use of a proprietary technology known as the Hemopurifier(TM), which is designed to rapidly reduce the presence of infectious disease and toxins in the body. The Hemopurifier converges the established scientific principals of affinity chromatography and hemodialysis as a means to augment the immune response of clearing viruses and toxins from the blood before cell and organ infection can occur. More information on Aethlon Medical and the Hemopurifier technology is available at www.aethlonmedical.com. Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion